Navigation Links
XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
Date:10/22/2007

No New MACE, Zero Late Stent Thrombosis - Company Also Provides Clinical Program Update and Will Host Webcast Mon.,

Oct. 22 at 7:00 a.m. ET -

WASHINGTON, Oct. 22 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced positive long-term follow-up data from the CUSTOM I and CUSTOM II single-arm prospective studies evaluating the safety and efficacy of its Custom NX(R) drug-eluting stent system in patients with coronary artery disease.

At one-year CUSTOM II clinical follow-up and at two-year CUSTOM I clinical follow-up, no new major adverse cardiac events (MACE) were reported. The incidence of late stent thrombosis for patients treated with Custom NX in both trials was zero percent.

"These long term results are exceptional. CUSTOM I and II are unlike any other early stage drug-eluting stent trial because of the lesion length and complexity of the patients treated in these trials," said Professor Eberhard Grube, M.D., chief of cardiology at the HELIOS Heart Center in Siegburg, Germany, and Principal Investigator of CUSTOM I and CUSTOM II. Professor Grube presented CUSTOM I two-year results and CUSTOM II one-year results during a satellite symposium Sunday evening at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) meeting.

Additionally, the company announced it recently filed its Investigational Device Exemption (IDE) to begin the CUSTOM IV pivotal trial and has now received questions back from the Food and Drug Administration (FDA). "Submission of our IDE was a significant milestone for the company and allows us to have clear discussions with the agency about the requirements necessary to gain approval to start the trial and continue our progress to bring Custom NX to physicians and patients," said Gregory D. Casciaro, President and CEO of XTENT. "We are quickly mobilizing to work with the FDA and as soon as we have spec
'/>"/>

SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Pa. , April 1, 2015  Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... pricing of an offering of $60.0 million aggregate ... 2020 (the "notes") in a private placement to ... the Securities Act of 1933, as amended (the ...
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/n9mxqs/an_introduction ) has ... the Medical Device Directives" conference to their offering. ... the European medical device legislation. It will explain the ... Notified Bodies, how to choose one and outline what ... documentation necessary to apply for the CE mark. ...
(Date:4/1/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... medical paper has been published describing the positive ... with severe dry eye.  The results met key ... stated that statistically significant differences in both signs ... at various time points throughout the study.  Of ...
Breaking Medicine Technology:Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Pricing of $60 Million Offering of Convertible Senior Notes Due 2020 7An Introduction to the Medical Device Directives Training: London, UK - 13th, 14th, 15th of May 2015 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
... May 5, 2011 Ridge Diagnostics, Inc., a ... at the 6th Annual Neurotech Investing and Partnering Conference to ... Hotel on May 9th and 10th.   Ms. ... panel entitled "Next Generation Psychiatry" lead by Dr. Manuel Lopez-Figueroa, ...
... INDIANAPOLIS, May 5, 2011 Eli Lilly and Company ... an Indianapolis-based nonprofit that supports bold, new education reform, ... What Works campaign. Grow What Works seeks to raise ... working in Indianapolis, enabling them to serve more students ...
Cached Medicine Technology:Ridge Diagnostics, Inc. CEO to Speak at Neurotech Investing and Partnering Conference 2Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trust's Grow What Works Campaign 2Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trust's Grow What Works Campaign 3Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trust's Grow What Works Campaign 4
(Date:4/1/2015)... Levi's® Stadium , located in Santa Clara is ... San Francisco 49ers from the National Football League call the ... Stadium has been the home of countless memorable events. Among ... far include a game from the 2015 National Hockey League ... Sharks, Wrestlemania 31 and an International Friendly Soccer Match between ...
(Date:4/1/2015)... 2015 This year for Oral Cancer Awareness ... Foundation for an Open House to offer complimentary oral cancer ... 4 p.m. An appointment is required and can be secured ... at 212-689-0024. In addition, Herald Square Dental and The Denture ... month of April at the reduced cost of $39 (regularly ...
(Date:4/1/2015)... NTOCC today launches the Knowledge & Resource ... seek to improve care transitions and positively impact health ... bring light to tools or resources that align with ... healthcare industry through the promotion of public policy, and ... that vision, the Knowledge & Resource Center serves as ...
(Date:4/1/2015)... The panel session will look at the need for ... program that can grow in a privacy-friendly manner, thus ... line. This topic has taken on even greater relevance ... dongles aren’t as secure as the automobile industry thought ... Progressive’s Snapshot dongles contained very significant security flaws, which ...
(Date:4/1/2015)... After a particularly harsh winter, many roads are ... to costly damage, so Amica Insurance has tips ... following suggestions from AAA: , , Inspect ... to the manufacturer’s recommended levels. , ... uneven tire wear can be signs of bad shocks or ...
Breaking Medicine News(10 mins):Health News:Levi's® Stadium Tickets for Super Bowl 50, Kenny Chesney & Jason Aldean, One Direction, Taylor Swift and Luke Bryan Available at Discounted Prices at TicketDown.com 2Health News:Levi's® Stadium Tickets for Super Bowl 50, Kenny Chesney & Jason Aldean, One Direction, Taylor Swift and Luke Bryan Available at Discounted Prices at TicketDown.com 3Health News:Herald Square Dental Celebrates Oral Cancer Awareness Month 2Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 2Health News:National Transitions of Care Coalition Launches Knowledge & Resource Center 3Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 3Health News:Prepare for potholes with 7 tips from Amica Insurance 2
... , CENTENNIAL, Colo., Dec. 17 AlloSource, ... and soft tissue allografts for use in surgical procedures and ... today announced that is has been selected as a finalist ... in the Samaritan Institute category honoring non-profits. This is the ...
... of Jerusalem Kuvin Center for the Study of Infectious ... from the Bill & Melinda Gates Foundation for research ... be led by Prof. Alon Warburg, a vector biologist ... the Hebrew University,s Faculty of Medicine. The project, ...
... its conclusion, negotiations are focusing on the role of ... from Deforestation and Forest Degradation, policy has gained widespread ... Since deforestation accounts for almost 20% of global ... countries to make a major contribution to emissions reduction. ...
... Vomiting syndrome made him a recluse at times, researcher ... Australian researcher claims he has identified the illness that ... vomiting, headaches and skin problems for most of his ... been suggested for the illness that could be so ...
... ... Human Resource Development Degree Online , ... Tampa, Fla. (PRWEB) December 17, 2009 -- Open enrollment has begun ... working professionals whose busy schedules can’t accommodate a campus-based program. With the university’s Master ...
... 17 Over the last few weeks there has been an ... e cigarette opposition in an attempt to scare the population concerning ... when the evidence clearly shows that the product is indeed a ... opinions from top medial and harm reduction specialist around the world. ...
Cached Medicine News:Health News:AlloSource Recognized for Exemplifying Ethics Amongst Colorado Non-Profits 2Health News:AlloSource Recognized for Exemplifying Ethics Amongst Colorado Non-Profits 3Health News:Hebrew U. receives $5 million for research on leishmaniasis in Ethiopia 2Health News:Forests take center stage at Copenhagen 2Health News:New Theory Emerges on Darwin's Illness 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:Special Interest Deceptions Continue to Rampant About Electronic Cigarettes 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: